15Oct

Validation of a Novel Risk Score for Severity of Illness in Acute Exacerbations of COPD

FILED IN medicine No Comments

Background: Clinicians lack a validated tool for risk stratification in acute exacerbations of COPD (AECOPD). We sought to validate the BAP-65 (elevated BUN, altered mental status, pulse > 109 beats/min, age > 65 years) score for this purpose.

Methods: We analyzed 34,699 admissions to 177 US hospitals (2007) with either a principal diagnosis of AECOPD or acute respiratory failure with a secondary diagnosis of AECOPD. Hospital mortality and need for mechanical ventilation (MV) served as co-primary end points. Length of stay (LOS) and costs represented secondary end points. We assessed the accuracy of BAP-65 via the area under the receiver operating characteristic curve (AUROC).

Results: Nearly 4% of subjects died while hospitalized and approximately 9% required MV. Mortality increased with increasing BAP-65 class, ranging from < 1% in subjects in class I (score of 0) to > 25% in those meeting all BAP-65 criteria (Cochran-Armitage trend test z = —38.48, P< .001). The need for MV also increased with escalating score (2% in the lowest risk cohort vs 55% in the highest risk group, Cochran-Armitage trend test z = —58.89, P < .001). The AUROC for BAP-65 for hospital mortality and/or need for MV measured 0.79 (95% CI, 0.78-0.80). The median LOS was 4 days, and mean hospital costs equaled $5,357. These also varied linearly with increasing BAP-65 score.

Conclusions: The BAP-65 system captures severity of illness Generic pharmacy viagra and represents a simple tool to categorize patients with AECOPD as to their risk for adverse outcomes. BAP-65 also correlates with measures of resource use. BAP-65 may represent a useful adjunct in the initial assessment of AECOPDs.

Abbreviations: AECOPD = acute exacerbations of COPD; AUROC = area under the receiver operating characteristic curve; BAP-65 = elevated BUN, altered mental status, pulse > 109 beats/min, age > 65 years; DRG = diagnosis-related group; ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; IQR = interquartile range; LOS = length of stay; MV = mechanical ventilation

COPD represents the fourth most common cause of death in the United States.

13Oct

Embolism scores exist to aid in the management of acute pulmonary embolism

FILED IN medicine No Comments

Beyond its impact on mortality, COPD leads to considerable morbidity. Acute exacerbations of COPD (AECOPDs) contribute to the disproportionate health burden of COPD. AECOPDs present a short-term risk for death and result in an accelerated decline in lung function. Patients often do not suffer a single exacerbation but tend to experience multiple exacerbations over their lifetimes. Furthermore, AECOPDs are a common reason for nonsurgical hospitalization and account for approximately one-half of the direct medical costs related to COPD.

AECOPDs can range in severity from mild to life threatening. Physicians can treat some individuals safely as outpatients. Other subjects may require mechanical ventilation (MV) for respiratory failure. In addition, some with AECOPD may initially respond to therapy but then decline. Unfortunately, clinicians lack a simple, validated risk-stratification tool for assessing the likely prognosis and severity of AECOPDs. For other diseases that share these features of variability in disease severity and the potential for a rapid change in patient status, clinicians can use various risk-stratification schemes. For example, both the Pneumonia Severity Index and the CURB-65 (confusion, urea, respiratory rate, BP) score serve as easy-to-apply and reliable severity-of-illness scoring rubrics in community-acquired pneumonia. The Pulmonary Embolism Severity Index and the Prognosis in Pulmonary

Embolism scores exist to aid in the management of acute pulmonary embolism. Unfortunately, although risk-assessment tools exist for patients with stable COPD, none have been validated for use in AECOPD.

A disease-specific severity-of-illness score for AECOPD would serve to improve treatment. It would facilitate triage decisions and identify patients who might potentially benefit for early and aggressive use of selected interventions, such as noninvasive ventilation. A reliable severity-of-illness score could also be applied in clinical trials. It would provide a standardized means for describing the patients studied while helping to ensure that the populations in these trials were well balanced with respect to disease severity.

TOP